Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-3-J obesity study of maridebart cafraglutide in Japanese adults
jRCT2031250134Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of maridebart cafraglutide in obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN) and 1 more (4 arms), sponsored by Amgen. Primary endpoints: Percent change from baseline in body weight at Week 72 and Participants achieving ≥5% reduction in body weight from baseline at Week 72. Started Jun 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on jRCT2031250134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250134.